GURU.Markets stock price, segment price, and overall market index valuation
The company's share price RAPT Therapeutics Inc.
RAPT Therapeutics is a biotech company developing oral medications for the treatment of inflammatory diseases. Its stock price is highly volatile and dependent on clinical trial results. The chart reflects the binary risks and hopes inherent in the sector.
Share prices of companies in the market segment - Pharma immune
RAPT Therapeutics (RAPT) is a biopharmaceutical company developing oral therapeutics for the treatment of inflammatory diseases and oncology, targeting key immune system proteins. We classify it in the Pharmaceuticals/Immunology sector. The chart below illustrates the dynamics of this cutting-edge biotech sector.
Broad Market Index - GURU.Markets
RAPT Therapeutics is a biopharmaceutical company developing oral medications for the treatment of inflammatory diseases and oncology. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how RAPT shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
RAPT - Daily change in the company's share price RAPT Therapeutics Inc.
Shares of RAPT Therapeutics, a biopharmaceutical company, are experiencing high volatility. Change_co measures the market reaction to clinical trial data in the field of immunology. This metric is an important component of formulas on System.GURU.Markets that evaluate innovative early-stage companies.
Daily change in the price of a set of shares in a market segment - Pharma immune
RAPT Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with RAPT, which focuses on immune disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
RAPT is a biopharmaceutical company specializing in drugs for the treatment of immune diseases. Immunology is a cutting-edge but highly volatile segment of biotechnology. The chart below shows average daily fluctuations in this area, allowing you to assess the performance of RAPT stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization RAPT Therapeutics Inc.
RAPT Therapeutics' year-to-date performance is a story about developing oral drugs for the treatment of inflammatory diseases and cancer. Its 12-month market cap is entirely dependent on clinical trial data. Any news about the safety and efficacy of its targeted molecules could dramatically change its valuation in the eyes of investors.
Annual dynamics of market capitalization of the market segment - Pharma immune
RAPT Therapeutics, Inc. is a clinical-stage biotech developing oral medications for the treatment of inflammatory diseases and cancer. Its stock performance is entirely dependent on clinical trial results. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
RAPT Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization RAPT Therapeutics Inc.
The market capitalization of RAPT, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about the progress of clinical trials of its drugs for the treatment of inflammatory diseases and cancer, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Immunology biotechnology is a promising yet unpredictable sector. Its dynamics, shown in the chart, reflect investor reactions to clinical trial results. In this high-stakes environment, companies like RAPT Therapeutics are developing new approaches to treating inflammatory diseases.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
RAPT Therapeutics, a biopharmaceutical company focused on immunology, thrives in a world of clinical data. Its shares rise and fall on trial news, defying overall market trends. This chart demonstrates this independence.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization RAPT Therapeutics Inc.
RAPT Therapeutics, a biotech company developing oral medications for the treatment of inflammatory diseases and cancer, is experiencing high volatility. Its weekly stock price is a direct reaction to the release of clinical trial data, which could dramatically change its valuation.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Biotech companies working in immunology, like RAPT Therapeutics, are riding the wave of general news about scientific breakthroughs in this field. The chart below illustrates this general sentiment. It allows one to assess how promising the market perceives RAPT's technology compared to developments by other companies in this field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
RAPT Therapeutics is a biotech company developing drugs to treat inflammatory diseases and cancer. Its shares are driven by news of clinical trials. The chart clearly demonstrates how their performance can be completely disconnected from overall market movements.
Market capitalization of the company, segment and market as a whole
RAPT - Market capitalization of the company RAPT Therapeutics Inc.
RAPT Therapeutics' market capitalization reflects investors' valuation of its approach to treating inflammatory diseases and cancer. The chart shows how the market values its targeted drugs, which block immune cell migration. Its high volatility is a direct response to clinical trial data, which determines the company's future.
RAPT - Share of the company's market capitalization RAPT Therapeutics Inc. within the market segment - Pharma immune
RAPT Therapeutics is a biopharmaceutical company developing oral drugs for the treatment of inflammatory diseases and cancer. In the immunology segment, its market capitalization reflects the potential of its platform. Its market capitalization is a sensitive indicator of clinical trial news, which could either confirm or refute the effectiveness of its approach.
Market capitalization of the market segment - Pharma immune
This chart shows the total value of the entire biotech sector specializing in immune therapy. For RAPT Therapeutics, which develops oral medications, this line demonstrates the scale of the market. The chart's growth reflects the enormous need for new, more convenient treatments for inflammatory diseases and cancer, where the company is seeking its niche.
Market capitalization of all companies included in a broad market index - GURU.Markets
RAPT Therapeutics develops oral medications for the treatment of inflammatory diseases and cancer. Its market cap is determined by the convenience and effectiveness of its approach. This represents the market share that investors allocate to developing pills instead of injections for complex diseases.
Book value capitalization of the company, segment and market as a whole
RAPT - Book value capitalization of the company RAPT Therapeutics Inc.
RAPT Therapeutics develops oral medications for the treatment of inflammatory diseases and cancer. Its book value represents its financial resources for R&D. It consists of cash that allows the company to conduct clinical trials. How has this vital capital changed? The chart below shows.
RAPT - Share of the company's book capitalization RAPT Therapeutics Inc. within the market segment - Pharma immune
RAPT Therapeutics develops oral medications for the treatment of inflammatory diseases and cancer. Its scientific work is supported by a proprietary drug discovery platform and state-of-the-art laboratories. The chart shows the company's share of the physical R&D infrastructure required to create next-generation small molecules.
Market segment balance sheet capitalization - Pharma immune
RAPT Therapeutics, a clinical-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
RAPT Therapeutics' capital is its scientific platform and development pipeline of oral drugs for the treatment of inflammatory diseases and cancer. Its book value reflects investments in research and clinical trials. The chart shows how this science-intensive asset is valued within the biotech sector.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - RAPT Therapeutics Inc.
RAPT's balance sheet is its R&D capital. Its entire market value is a premium for its scientific platform for developing oral drugs for the treatment of inflammatory diseases and oncology. Its schedule is a bet on the success of its clinical programs.
Market to book capitalization ratio in a market segment - Pharma immune
RAPT Therapeutics is a biotech company developing drugs to treat inflammatory diseases and cancer. Its high valuation on this chart reflects investors' faith in its scientific approach and the potential of its developments, which target new biological targets.
Market to book capitalization ratio for the market as a whole
RAPT Therapeutics is a biotech company developing oral medications for the treatment of inflammatory diseases and cancer. Its market value depends on progress in clinical trials. This chart shows how expectations and development news drive its valuation independent of its current tangible assets.
Debts of the company, segment and market as a whole
RAPT - Company debts RAPT Therapeutics Inc.
RAPT Therapeutics, a clinical-stage biopharmaceutical company developing drugs to treat inflammatory diseases and cancer, uses capital to fund its research. This chart shows how the company manages its resources to advance its molecules through the expensive and risky clinical trials process.
Market segment debts - Pharma immune
RAPT Therapeutics is a clinical-stage biotech company developing drugs for the treatment of inflammatory diseases and cancer. Funding at this stage relies almost entirely on equity. This chart illustrates a typical industry-standard financial model with minimal or no leverage.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio RAPT Therapeutics Inc.
RAPT Therapeutics is a biotech company focused on immunology. Funding clinical trials is its primary objective and expense. This chart shows how much the company relies on debt to advance its research. It reflects the financial risk investors are taking when betting on the future success of its drugs.
Market segment debt to market segment book capitalization - Pharma immune
RAPT Therapeutics develops oral drugs to treat inflammatory diseases and cancer. Creating pills instead of injections is a significant advantage. The chart shows how aggressively the biotech sector uses debt to fund R&D, which helps assess how RAPT finances its clinical programs.
Debt to book value of all companies in the market
RAPT Therapeutics, a clinical-stage immunology company, requires significant investment to advance its development through costly trials. This chart, reflecting the overall market debt burden, allows one to assess how typical the company's financial strategy is for the biotech sector, where revenue is deferred indefinitely.
P/E of the company, segment and market as a whole
P/E - RAPT Therapeutics Inc.
RAPT Therapeutics is a biopharmaceutical company developing oral medications for the treatment of inflammatory diseases and oncology. This chart shows how investors value its scientific platform. This valuation depends on the success of clinical trials and the potential of its drugs to offer convenient and effective treatment.
P/E of the market segment - Pharma immune
RAPT Therapeutics develops oral medications for the treatment of inflammation. This chart shows the average valuation for the biotech sector. It serves as a backdrop for RAPT's valuation: investors are looking not at its profits, but at the potential of its developments to offer convenient treatments to millions of patients.
P/E of the market as a whole
RAPT Therapeutics is a biopharmaceutical company developing small-molecule drugs for the treatment of inflammatory diseases and oncology by modulating key immune responses. This chart reflects the overall risk appetite of investors in biotech. It helps understand whether RAPT's valuation is based on the potential of its scientific developments or whether it moves in tandem with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company RAPT Therapeutics Inc.
RAPT Therapeutics develops oral medications for the treatment of inflammatory diseases and cancer. Future profits depend on the success of its clinical trials. This chart shows investor expectations regarding the potential of its molecules to become new treatment standards in their therapeutic areas.
%20P%2FE%20RAPT%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-RAPT-Therapeutics-Inc.&v=1772610131095 "Chart of the company's future (projected) P/E RAPT Therapeutics Inc.")
Future (projected) P/E of the market segment - Pharma immune
RAPT Therapeutics develops oral drugs for the treatment of inflammatory diseases and oncology, targeting the regulation of immune cell migration. The data here reflects the analysts' collective bet on the success of its clinical programs. It is a barometer of expectations that its approach will prove effective and safe for the treatment of a wide range of diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772610131097 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
RAPT Therapeutics develops oral medications for the treatment of inflammatory diseases and cancer. Their approach could offer a more convenient alternative to injections. This general sentiment chart shows how much investors value innovations that are aimed not only at efficacy but also at improving patients' quality of life.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772610131097 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit RAPT Therapeutics Inc.
RAPT Therapeutics is a biotech company developing oral medications for the treatment of inflammatory diseases and cancer. This chart shows the financial costs of clinical trials. It reflects investments in developing more convenient and effective treatments compared to existing injectables.
Profit of companies in the market segment - Pharma immune
RAPT Therapeutics is a biopharmaceutical company developing oral drugs for the treatment of inflammatory diseases and cancer. Being in the clinical stage, its financial history is one of investment in research. The potential success of its developments could significantly contribute to profitability in its respective therapeutic areas.
Overall market profit
RAPT Therapeutics is a biotech company developing oral medications for the treatment of inflammatory diseases and cancer. Its success depends on the results of clinical trials. The overall economic situation, reflected in this chart, does not affect the need for treatment, but it does impact financial markets, which affect the company's ability to fund its R&D programs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company RAPT Therapeutics Inc.
RAPT Therapeutics is a biotech company developing oral drugs for the treatment of inflammatory diseases and oncology. This chart shows analysts' speculative expectations. Future profits depend entirely on the success of clinical trials and the market penetration of their candidates.
%20profit%20of%20the%20company%20RAPT%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-RAPT-Therapeutics-Inc.&v=1772610131102 "Graph of future (projected) profit of the company RAPT Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
RAPT Therapeutics develops oral drugs for the treatment of inflammatory diseases and cancer. The profitability projections for the pharmaceutical industry, shown in this chart, provide a general overview. This chart helps assess the potential of RAPT's targeted approach to create effective and patient-friendly medications.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772610131110 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
RAPT Therapeutics is a biotech company developing drugs to treat inflammatory diseases and cancer. Its prospects depend on the results of clinical trials. Raising the capital needed for these trials is easier in a strong stock market, which often accompanies a positive outlook on this chart.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772610131116 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - RAPT Therapeutics Inc.
RAPT Therapeutics is a biopharmaceutical company developing oral medications for the treatment of inflammatory diseases and cancer. Being in the clinical stage, it may not generate revenue. This chart shows how investors view its scientific platform and the potential of its drug candidates to treat a wide range of diseases.
P/S market segment - Pharma immune
RAPT Therapeutics is a biopharmaceutical company developing oral drugs for the treatment of inflammatory diseases and oncology. This chart shows the average revenue estimate in the biotech sector. It helps assess the market's confidence in the company's platform's potential compared to the industry average.
P/S of the market as a whole
RAPT Therapeutics is a biopharmaceutical company developing oral therapies for the treatment of inflammatory diseases and cancer. The company's approach is based on the modulation of key immune cell signaling pathways. This chart compares how the market values companies based on current revenue, which is important for analyzing clinical-stage biotechs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company RAPT Therapeutics Inc.
RAPT Therapeutics is a biotech company developing oral therapies for the treatment of inflammatory diseases and cancer. This chart reflects investor estimates of its potential future revenue. This estimate is a bet on the success of its clinical programs and the need for convenient oral therapies.
%20P%2FS%20RAPT%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-RAPT-Therapeutics-Inc.&v=1772610131149 "The graph of the company's future (projected) P/S RAPT Therapeutics Inc.")
Future (projected) P/S of the market segment - Pharma immune
RAPT Therapeutics is a biopharmaceutical company developing oral therapies for the treatment of inflammatory diseases and cancer. This chart compares market expectations for its future revenue with other immune pharma companies. The valuation reflects investor confidence in the potential of its platform to develop new treatments.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772610131150 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
RAPT Therapeutics is a clinical-stage biotechnology company developing drugs for the treatment of inflammatory diseases and cancer. Its valuation depends on the success of clinical trials. This graph of overall market expectations for RAPT is merely a backdrop; its future is determined by the results of its scientific programs and the potential of its drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772610131150 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales RAPT Therapeutics Inc.
This chart illustrates the revenue of RAPT Therapeutics, a biotech company developing oral medications for the treatment of inflammatory diseases and cancer. Being in the clinical stage, the company has no stable sales revenue. A chart with zero or low revenue is normal, as all activities are focused on clinical trials.
Sales of companies in the market segment - Pharma immune
RAPT Therapeutics is a biopharmaceutical company developing oral therapies for the treatment of inflammatory diseases and cancer by modulating key immune responses. This chart shows revenue in the immunological pharmaceuticals sector. It reflects the significant potential of targeted therapies targeting the immune system for treating a wide range of diseases, which is RAPT's focus.
Overall market sales
RAPT Therapeutics is a biotech company developing drugs to treat inflammatory diseases and cancer. Its valuation depends on the results of clinical trials. The overall economic situation, reflected in this chart, does not directly affect the need for treatment, but it does influence the investment climate in the biotech sector, which is essential for funding R&D.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company RAPT Therapeutics Inc.
RAPT Therapeutics is a clinical-stage immunology company developing oral therapies for the treatment of inflammatory diseases and cancer. This revenue projection chart reflects expectations for its research and development. Its dynamics depend on analysts' confidence in the successful clinical trial results of its drug candidates.
%20sales%20of%20the%20company%20RAPT%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-RAPT-Therapeutics-Inc.&v=1772610131161 "Schedule of future (projected) sales of the company RAPT Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
RAPT Therapeutics is a biopharmaceutical company developing oral therapies for the treatment of inflammatory diseases and oncology. Their approach is based on modulating immune cell migration. This chart shows projected revenues for the entire immunopharmaceutical sector, reflecting the search for new ways to manipulate the body's immune response.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772610131163 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
RAPT Therapeutics is a biotech company developing drugs for the treatment of inflammatory diseases and cancer. Its future depends on the results of clinical trials. Positive economic forecasts create a favorable investment climate, allowing companies like RAPT to raise funds for long-term and expensive research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772610131163 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality RAPT Therapeutics Inc.
RAPT Therapeutics is a biotech company developing oral drugs for the treatment of inflammatory diseases and oncology. Being in the clinical stage, it relies entirely on investor capital. This chart shows the cost of its research and development, reflecting the operating losses incurred on the path to developing marketable drugs.
Market segment marginality - Pharma immune
RAPT Therapeutics is a biopharmaceutical company developing oral drugs for the treatment of inflammatory diseases and oncology. This chart compares its operating efficiency with other biotech companies. Its current competitive advantage may be due to upfront payments from drug development partners or more cost-effective research.
Market marginality as a whole
RAPT Therapeutics is a biotech company developing oral medications for the treatment of inflammatory diseases and cancer. Its success depends solely on the results of clinical trials, not on the economic situation, as reflected in this chart. The need for effective and convenient treatments for chronic diseases is a constant driver.
Employees in the company, segment and market as a whole
Number of employees in the company RAPT Therapeutics Inc.
RAPT Therapeutics is a biotech company developing oral medications for the treatment of inflammatory diseases and cancer. This chart shows the team of scientists and clinicians. The headcount dynamics reflect the progress of clinical trials and investor confidence in the company's scientific platform.
Share of the company's employees RAPT Therapeutics Inc. within the market segment - Pharma immune
RAPT Therapeutics is a clinical-stage biotech company specializing in drugs for the treatment of inflammatory diseases and cancer. Its team is a focused group of scientists. This graph reflects its current status: its small staff means the company is fully focused on conducting clinical trials for its candidates.
Number of employees in the market segment - Pharma immune
RAPT Therapeutics is a biotech company developing oral drugs for the treatment of inflammatory diseases and oncology. This graph shows the company's development trajectory with a platform technology. The research staff's growth reflects progress across multiple clinical programs, diversifying risks compared to companies with a single product.
Number of employees in the market as a whole
RAPT Therapeutics is a biopharmaceutical company developing oral medications for the treatment of inflammatory diseases and cancer. Its staff consists of highly qualified researchers. This overall employment chart shows that hiring trends in the biotech sector are driven not by the state of the economy, but by progress in drug development and R&D capital.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company RAPT Therapeutics Inc. (RAPT)
RAPT Therapeutics is a biopharmaceutical company developing oral drugs for the treatment of inflammatory diseases and cancer. This chart shows the enormous market value associated with a single scientist. This is a classic example of a clinical-stage biotech, where market capitalization reflects investor expectations for the success of clinical trials and future sales.
%20of%20the%20company%20RAPT%20Therapeutics%20Inc.%20(RAPT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-RAPT-Therapeutics-Inc.-RAPT&v=1772610131185 "Chart of market capitalization per employee (in thousands of dollars) of the company RAPT Therapeutics Inc. (RAPT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
RAPT Therapeutics is a biopharmaceutical company developing oral drugs for the treatment of inflammatory diseases and cancer. This chart reflects market expectations for their scientific platform. A high market capitalization per employee may indicate that investors believe in the breakthrough potential of their treatment approach and highly value their research team.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772610131186 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
RAPT Therapeutics is a biopharmaceutical company developing oral medications for the treatment of inflammatory diseases and cancer. This metric reflects a business built on scientific research. Its market capitalization is a function of the prospects of its developments. A small team of scientists is working to create convenient and effective medications.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772610131187 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company RAPT Therapeutics Inc. (RAPT)
RAPT Therapeutics is a clinical-stage biotech company working in the field of immunology (treating cancer and inflammatory diseases). They are not profitable. This chart shows their loss per employee. This is a standard indicator of the "burn rate" of capital spent on expensive clinical trials.
%20Chart%20RAPT%20Therapeutics%20Inc.%20(RAPT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-RAPT-Therapeutics-Inc.-RAPT&v=1772610131199 "Company Profit Per Employee (in thousands of dollars) Chart RAPT Therapeutics Inc. (RAPT)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
RAPT Therapeutics is a biotech company specializing in the treatment of inflammatory diseases and cancer. Being in the clinical stage, it is not profitable and incurs R&D expenses. This chart allows investors to compare RAPT's capital efficiency (costs per employee) with other biotech companies.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772610131213 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
RAPT Therapeutics is a clinical-stage biotech company focused on immune diseases and oncology. They are developing new classes of drugs. This graph shows the "cost of science"—a negative value reflecting the investment spent on each employee in the development and testing of new drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772610131219 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee RAPT Therapeutics Inc. (RAPT)
RAPT Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of inflammatory diseases and cancer. This schedule is typical for a biotech company in the R&D phase. No revenue per employee is the norm for a company whose value is determined by the potential of its scientific developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-RAPT-Therapeutics-Inc.-RAPT&v=1772610131220 "Sales chart per company employee RAPT Therapeutics Inc. (RAPT)")
Sales per employee in the market segment - Pharma immune
RAPT Therapeutics (RAPT) is a biotech company specializing in the development of oral (tablet-based) drugs for the treatment of inflammatory diseases and oncology. This chart shows how much revenue (from partnerships) each employee (scientist) generates. This is an indicator of the productivity of their R&D platform compared to other biotechs.
Sales per employee for the market as a whole
RAPT Therapeutics is a clinical-stage biopharmaceutical company developing oral medications for the treatment of inflammatory diseases and oncology. This is an R&D business. The company has no commercial revenue from drug sales. This metric is currently close to zero and does not reflect operating activities.
Short shares by company, segment and market as a whole
Shares shorted by company RAPT Therapeutics Inc. (RAPT)
RAPT Therapeutics is a biotech company specializing in the treatment of inflammatory diseases and cancer. This chart measures bearish bets. Bears are betting on high risk: one of the company's key drugs has been suspended by regulators due to safety concerns, casting doubt on the entire platform.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-RAPT-Therapeutics-Inc.-RAPT&v=1772610131223 "Short Shares Chart for the Company RAPT Therapeutics Inc. (RAPT)")
Shares shorted by market segment - Pharma immune
RAPT Therapeutics is a biotech company developing drugs for the treatment of inflammatory diseases (such as atopic dermatitis) and cancer. This indicator reflects skepticism. The "short" here is a bet that their clinical trials will fail (possibly due to side effects).
Shares shorted by the overall market
RAPT Therapeutics is a biotech developing oral drugs for the treatment of inflammatory diseases and oncology. This chart reflects the overall market pessimism. When fear dominates the market, biotech stocks with drugs still in development become extremely volatile. Investors prioritize safety over scientific prospects.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator RAPT Therapeutics Inc. (RAPT)
RAPT Therapeutics (RAPT) is a biotech company developing oral (tablet) drugs for the treatment of inflammatory diseases (such as atopic dermatitis) and cancer. This chart measures hype. It shows "overheated" (above 70) on positive R&D data or "oversold" (below 30) on news of trial pauses or adverse events.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-RAPT-Therapeutics-Inc.-RAPT&v=1772610131240 "RSI 14 indicator chart for the company's stock RAPT Therapeutics Inc. (RAPT)")
RSI 14 Market Segment - Pharma immune
RAPT Therapeutics (RAPT) is a biotech company developing oral (tablet) drugs for the treatment of inflammatory diseases (such as dermatitis). The RSI_14_Seg for "Pharma-Immune" shows whether the entire biotech segment is overheated. The chart helps us understand whether RAPT's volatility is a reaction to its trials or just general hype.
RSI 14 for the overall market
RAPT Therapeutics (RAPT) is a biotech company. Like everything in its sector, it's critically dependent on this timeline. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RAPT (RAPT Therapeutics Inc.)
RAPT Therapeutics is a biotech company developing oral (tablet-based) drugs for the treatment of inflammatory diseases and oncology. This chart shows the average 12-month analyst forecast. Their target price is heavily dependent on the progress of clinical trials, especially after past safety failures.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RAPT-RAPT-Therapeutics-Inc.&v=1772610131284 "A chart showing analyst consensus forecasts for the expected stock price. RAPT (RAPT Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price RAPT (RAPT Therapeutics Inc.)
RAPT Therapeutics is a biotech company developing oral (tablet) drugs for the treatment of complex inflammatory diseases (e.g., atopic dermatitis). This chart measures the gap between the current share price and the consensus target price. It shows the potential analysts see in their clinical development pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RAPT-RAPT-Therapeutics-Inc.&v=1772610131286 "A chart showing the difference between the consensus forecast and the actual stock price. RAPT (RAPT Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
RAPT Therapeutics is a biotech company developing oral medications (tablets) for the treatment of inflammatory diseases and oncology. This chart shows analysts' overall expectations for the immune pharma sector. It reflects the experts' confidence in the success of the company's R&D pipeline and its platform as a whole.
Analysts' consensus forecast for the overall market share price
RAPT Therapeutics is a biotech company developing oral (tablet) drugs for the treatment of inflammatory diseases (atopic dermatitis) and cancer. This chart shows the overall risk appetite. For RAPT, as a clinical-stage company, overall market optimism is critical to raising the capital needed to fund long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index RAPT Therapeutics Inc.
RAPT Therapeutics is a clinical-stage biotech company focused on immunology. They develop oral (tablet-based) drugs for the treatment of inflammatory diseases (atopic dermatitis) and cancer. This graph is a pure assessment of their R&D pipeline. Its dynamics depend entirely on their progress in clinical trials and the market's confidence in their scientific approach.
AKIMA Market Segment Index - Pharma immune
RAPT Therapeutics (RAPT) is a clinical-stage biotech focused on immunology; the company develops oral (tablet-based) drugs for the treatment of inflammatory diseases (dermatitis) and cancer. This summary metric evaluates R&D. The chart shows the segment average. This benchmark: how does this R&D platform (RAPT) (and its recent setbacks) compare to the average pharma company?
The AKIM Index for the overall market
RAPT Therapeutics is a biotech company developing oral medications for the treatment of inflammatory diseases (eczema) and cancer. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this clinical story, which is facing regulatory delays, compares to the overall economic trends affecting biotech.
